Clinical Research Papers:
Diffusion-weighted MR imaging in prediction of response to neoadjuvant chemotherapy in patients with breast cancer
Metrics: PDF 891 views | HTML 1631 views | ?
Xue-Ying Hu1,*, Ying Li1,*, Guan-Qiao Jin1, Shao-Lv Lai1, Xiang-Yang Huang1 and Dan-Ke Su1
1 Department of Radiology, Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
* Authors contributed equally to this work
Dan-Ke Su, email:
Keywords: MRI, apparent diffusion coefficient, neoadjuvant chemotherapy, breast cancer
Received: February 06, 2017 Accepted: June 18, 2017 Published: July 05, 2017
This study aims to evaluate the potential of apparent diffusion coefficient (ADC) derived from diffusion-weighted MR imaging for predicting the treatment response to neoadjuvant chemotherapy (NACT) in patients with breast cancer. Magnetic resonance imaging was performed prior to NACT and after two cycles of NACT. The correlation between mean ADCpre values, mean ADCpost values, changes in ADC values and changes in tumor diameters after NACT was examined using Spearman rank correlation. A total of 164 breast cancers were enrolled in this study. Mean ADCpre values of responders ([0.85 ± 0.16] × 10-3 mm2/s) and non-responders ([0.84 ± 0.21] × 10-3 mm2/s) had no significant difference (P = 0.759). While mean ADCpost value of responders was significantly higher than that of non-responders ([1.17 ± 0.37] × 10-3 mm2/s vs. [1.01 ± 0.28] × 10-3 mm2/s; P = 0.002). Both mean ADCpost values (r = 0.288, P = 0.000) and changes in mean ADC values (r = 0.222, P = 0.004) were positively correlated to changes in tumor diameter after NACT, except for mean ADCpre values (r = 0.031, P = 0.695). Our results indicated that mean ADCpost values and changes in ADC values after NACT might be a biological marker for assessing the efficacy of chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.